

Global VEGF Inhibitor Drugs Market Research Report 2023

<https://marketpublishers.com/r/G556FE525FB2EN.html>

Date: December 2023

Pages: 86

Price: US\$ 2,900.00 (Single User License)

ID: G556FE525FB2EN

Abstracts

Vascular endothelial growth factor (VEGF) is an angiogenic factor responsible for the formation of blood vessels either from already existing blood vessels or from vascular endothelial cells.

According to QYResearch's new survey, global VEGF Inhibitor Drugs market is projected to reach US\$ 14460 million in 2029, increasing from US\$ 8271 million in 2022, with the CAGR of 8.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole VEGF Inhibitor Drugs market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global VEGF Inhibitor Drugs market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Pfizer

Novartis AG

GlaxoSmithKline plc

Sanofi

AstraZeneca plc

Bristol-Myers-Squibb Company

Genentech, Inc. (Roche)

Merck & Co., Inc.

Bayer AG

Eli Lilly & Company

Segment by Type

Tyrosine Kinase Inhibitors

Monoclonal Antibodies

Others

Segment by Application

Oncology

Ophthalmology

Others

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The VEGF Inhibitor Drugs report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type
 - 1.2.1 Global VEGF Inhibitor Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
 - 1.2.2 Tyrosine Kinase Inhibitors
 - 1.2.3 Monoclonal Antibodies
 - 1.2.4 Others
- 1.3 Market by Application
 - 1.3.1 Global VEGF Inhibitor Drugs Market Growth by Application: 2018 VS 2022 VS 2029
 - 1.3.2 Oncology
 - 1.3.3 Ophthalmology
 - 1.3.4 Others
- 1.4 Study Objectives
- 1.5 Years Considered
- 1.6 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Global VEGF Inhibitor Drugs Market Perspective (2018-2029)
- 2.2 VEGF Inhibitor Drugs Growth Trends by Region
 - 2.2.1 Global VEGF Inhibitor Drugs Market Size by Region: 2018 VS 2022 VS 2029
 - 2.2.2 VEGF Inhibitor Drugs Historic Market Size by Region (2018-2023)
 - 2.2.3 VEGF Inhibitor Drugs Forecasted Market Size by Region (2024-2029)
- 2.3 VEGF Inhibitor Drugs Market Dynamics
 - 2.3.1 VEGF Inhibitor Drugs Industry Trends
 - 2.3.2 VEGF Inhibitor Drugs Market Drivers
 - 2.3.3 VEGF Inhibitor Drugs Market Challenges
 - 2.3.4 VEGF Inhibitor Drugs Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

- 3.1 Global Top VEGF Inhibitor Drugs Players by Revenue
 - 3.1.1 Global Top VEGF Inhibitor Drugs Players by Revenue (2018-2023)
 - 3.1.2 Global VEGF Inhibitor Drugs Revenue Market Share by Players (2018-2023)

3.2 Global VEGF Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by VEGF Inhibitor Drugs Revenue

3.4 Global VEGF Inhibitor Drugs Market Concentration Ratio

3.4.1 Global VEGF Inhibitor Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by VEGF Inhibitor Drugs Revenue in 2022

3.5 VEGF Inhibitor Drugs Key Players Head office and Area Served

3.6 Key Players VEGF Inhibitor Drugs Product Solution and Service

3.7 Date of Enter into VEGF Inhibitor Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 VEGF INHIBITOR DRUGS BREAKDOWN DATA BY TYPE

4.1 Global VEGF Inhibitor Drugs Historic Market Size by Type (2018-2023)

4.2 Global VEGF Inhibitor Drugs Forecasted Market Size by Type (2024-2029)

5 VEGF INHIBITOR DRUGS BREAKDOWN DATA BY APPLICATION

5.1 Global VEGF Inhibitor Drugs Historic Market Size by Application (2018-2023)

5.2 Global VEGF Inhibitor Drugs Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America VEGF Inhibitor Drugs Market Size (2018-2029)

6.2 North America VEGF Inhibitor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America VEGF Inhibitor Drugs Market Size by Country (2018-2023)

6.4 North America VEGF Inhibitor Drugs Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe VEGF Inhibitor Drugs Market Size (2018-2029)

7.2 Europe VEGF Inhibitor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe VEGF Inhibitor Drugs Market Size by Country (2018-2023)

7.4 Europe VEGF Inhibitor Drugs Market Size by Country (2024-2029)

7.5 Germany

- 7.6 France
- 7.7 U.K.
- 7.8 Italy
- 7.9 Russia
- 7.10 Nordic Countries

8 ASIA-PACIFIC

- 8.1 Asia-Pacific VEGF Inhibitor Drugs Market Size (2018-2029)
- 8.2 Asia-Pacific VEGF Inhibitor Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
- 8.3 Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2018-2023)
- 8.4 Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2024-2029)
- 8.5 China
- 8.6 Japan
- 8.7 South Korea
- 8.8 Southeast Asia
- 8.9 India
- 8.10 Australia

9 LATIN AMERICA

- 9.1 Latin America VEGF Inhibitor Drugs Market Size (2018-2029)
- 9.2 Latin America VEGF Inhibitor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 9.3 Latin America VEGF Inhibitor Drugs Market Size by Country (2018-2023)
- 9.4 Latin America VEGF Inhibitor Drugs Market Size by Country (2024-2029)
- 9.5 Mexico
- 9.6 Brazil

10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa VEGF Inhibitor Drugs Market Size (2018-2029)
- 10.2 Middle East & Africa VEGF Inhibitor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 10.3 Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2018-2023)
- 10.4 Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2024-2029)
- 10.5 Turkey
- 10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Pfizer

- 11.1.1 Pfizer Company Detail
- 11.1.2 Pfizer Business Overview
- 11.1.3 Pfizer VEGF Inhibitor Drugs Introduction
- 11.1.4 Pfizer Revenue in VEGF Inhibitor Drugs Business (2018-2023)
- 11.1.5 Pfizer Recent Development

11.2 Novartis AG

- 11.2.1 Novartis AG Company Detail
- 11.2.2 Novartis AG Business Overview
- 11.2.3 Novartis AG VEGF Inhibitor Drugs Introduction
- 11.2.4 Novartis AG Revenue in VEGF Inhibitor Drugs Business (2018-2023)
- 11.2.5 Novartis AG Recent Development

11.3 GlaxoSmithKline plc

- 11.3.1 GlaxoSmithKline plc Company Detail
- 11.3.2 GlaxoSmithKline plc Business Overview
- 11.3.3 GlaxoSmithKline plc VEGF Inhibitor Drugs Introduction
- 11.3.4 GlaxoSmithKline plc Revenue in VEGF Inhibitor Drugs Business (2018-2023)
- 11.3.5 GlaxoSmithKline plc Recent Development

11.4 Sanofi

- 11.4.1 Sanofi Company Detail
- 11.4.2 Sanofi Business Overview
- 11.4.3 Sanofi VEGF Inhibitor Drugs Introduction
- 11.4.4 Sanofi Revenue in VEGF Inhibitor Drugs Business (2018-2023)
- 11.4.5 Sanofi Recent Development

11.5 AstraZeneca plc

- 11.5.1 AstraZeneca plc Company Detail
- 11.5.2 AstraZeneca plc Business Overview
- 11.5.3 AstraZeneca plc VEGF Inhibitor Drugs Introduction
- 11.5.4 AstraZeneca plc Revenue in VEGF Inhibitor Drugs Business (2018-2023)
- 11.5.5 AstraZeneca plc Recent Development

11.6 Bristol-Myers-Squibb Company

- 11.6.1 Bristol-Myers-Squibb Company Company Detail
- 11.6.2 Bristol-Myers-Squibb Company Business Overview
- 11.6.3 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Introduction
- 11.6.4 Bristol-Myers-Squibb Company Revenue in VEGF Inhibitor Drugs Business

(2018-2023)

11.6.5 Bristol-Myers-Squibb Company Recent Development

11.7 Genentech, Inc. (Roche)

11.7.1 Genentech, Inc. (Roche) Company Detail

11.7.2 Genentech, Inc. (Roche) Business Overview

11.7.3 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Introduction

11.7.4 Genentech, Inc. (Roche) Revenue in VEGF Inhibitor Drugs Business

(2018-2023)

11.7.5 Genentech, Inc. (Roche) Recent Development

11.8 Merck & Co., Inc.

11.8.1 Merck & Co., Inc. Company Detail

11.8.2 Merck & Co., Inc. Business Overview

11.8.3 Merck & Co., Inc. VEGF Inhibitor Drugs Introduction

11.8.4 Merck & Co., Inc. Revenue in VEGF Inhibitor Drugs Business (2018-2023)

11.8.5 Merck & Co., Inc. Recent Development

11.9 Bayer AG

11.9.1 Bayer AG Company Detail

11.9.2 Bayer AG Business Overview

11.9.3 Bayer AG VEGF Inhibitor Drugs Introduction

11.9.4 Bayer AG Revenue in VEGF Inhibitor Drugs Business (2018-2023)

11.9.5 Bayer AG Recent Development

11.10 Eli Lilly & Company

11.10.1 Eli Lilly & Company Company Detail

11.10.2 Eli Lilly & Company Business Overview

11.10.3 Eli Lilly & Company VEGF Inhibitor Drugs Introduction

11.10.4 Eli Lilly & Company Revenue in VEGF Inhibitor Drugs Business (2018-2023)

11.10.5 Eli Lilly & Company Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global VEGF Inhibitor Drugs Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Tyrosine Kinase Inhibitors

Table 3. Key Players of Monoclonal Antibodies

Table 4. Key Players of Others

Table 5. Global VEGF Inhibitor Drugs Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 6. Global VEGF Inhibitor Drugs Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 7. Global VEGF Inhibitor Drugs Market Size by Region (2018-2023) & (US\$ Million)

Table 8. Global VEGF Inhibitor Drugs Market Share by Region (2018-2023)

Table 9. Global VEGF Inhibitor Drugs Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 10. Global VEGF Inhibitor Drugs Market Share by Region (2024-2029)

Table 11. VEGF Inhibitor Drugs Market Trends

Table 12. VEGF Inhibitor Drugs Market Drivers

Table 13. VEGF Inhibitor Drugs Market Challenges

Table 14. VEGF Inhibitor Drugs Market Restraints

Table 15. Global VEGF Inhibitor Drugs Revenue by Players (2018-2023) & (US\$ Million)

Table 16. Global VEGF Inhibitor Drugs Market Share by Players (2018-2023)

Table 17. Global Top VEGF Inhibitor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Inhibitor Drugs as of 2022)

Table 18. Ranking of Global Top VEGF Inhibitor Drugs Companies by Revenue (US\$ Million) in 2022

Table 19. Global 5 Largest Players Market Share by VEGF Inhibitor Drugs Revenue (CR5 and HHI) & (2018-2023)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players VEGF Inhibitor Drugs Product Solution and Service

Table 22. Date of Enter into VEGF Inhibitor Drugs Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global VEGF Inhibitor Drugs Market Size by Type (2018-2023) & (US\$ Million)

Table 25. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2018-2023)

Table 26. Global VEGF Inhibitor Drugs Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 27. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2024-2029)

Table 28. Global VEGF Inhibitor Drugs Market Size by Application (2018-2023) & (US\$ Million)

Table 29. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2018-2023)

Table 30. Global VEGF Inhibitor Drugs Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 31. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2024-2029)

Table 32. North America VEGF Inhibitor Drugs Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 33. North America VEGF Inhibitor Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 34. North America VEGF Inhibitor Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 35. Europe VEGF Inhibitor Drugs Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 36. Europe VEGF Inhibitor Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 37. Europe VEGF Inhibitor Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 38. Asia-Pacific VEGF Inhibitor Drugs Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 39. Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2018-2023) & (US\$ Million)

Table 40. Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2024-2029) & (US\$ Million)

Table 41. Latin America VEGF Inhibitor Drugs Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 42. Latin America VEGF Inhibitor Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 43. Latin America VEGF Inhibitor Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 44. Middle East & Africa VEGF Inhibitor Drugs Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 45. Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2018-2023) & (US\$ Million)

- Table 46. Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2024-2029) & (US\$ Million)
- Table 47. Pfizer Company Detail
- Table 48. Pfizer Business Overview
- Table 49. Pfizer VEGF Inhibitor Drugs Product
- Table 50. Pfizer Revenue in VEGF Inhibitor Drugs Business (2018-2023) & (US\$ Million)
- Table 51. Pfizer Recent Development
- Table 52. Novartis AG Company Detail
- Table 53. Novartis AG Business Overview
- Table 54. Novartis AG VEGF Inhibitor Drugs Product
- Table 55. Novartis AG Revenue in VEGF Inhibitor Drugs Business (2018-2023) & (US\$ Million)
- Table 56. Novartis AG Recent Development
- Table 57. GlaxoSmithKline plc Company Detail
- Table 58. GlaxoSmithKline plc Business Overview
- Table 59. GlaxoSmithKline plc VEGF Inhibitor Drugs Product
- Table 60. GlaxoSmithKline plc Revenue in VEGF Inhibitor Drugs Business (2018-2023) & (US\$ Million)
- Table 61. GlaxoSmithKline plc Recent Development
- Table 62. Sanofi Company Detail
- Table 63. Sanofi Business Overview
- Table 64. Sanofi VEGF Inhibitor Drugs Product
- Table 65. Sanofi Revenue in VEGF Inhibitor Drugs Business (2018-2023) & (US\$ Million)
- Table 66. Sanofi Recent Development
- Table 67. AstraZeneca plc Company Detail
- Table 68. AstraZeneca plc Business Overview
- Table 69. AstraZeneca plc VEGF Inhibitor Drugs Product
- Table 70. AstraZeneca plc Revenue in VEGF Inhibitor Drugs Business (2018-2023) & (US\$ Million)
- Table 71. AstraZeneca plc Recent Development
- Table 72. Bristol-Myers-Squibb Company Company Detail
- Table 73. Bristol-Myers-Squibb Company Business Overview
- Table 74. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product
- Table 75. Bristol-Myers-Squibb Company Revenue in VEGF Inhibitor Drugs Business (2018-2023) & (US\$ Million)
- Table 76. Bristol-Myers-Squibb Company Recent Development
- Table 77. Genentech, Inc. (Roche) Company Detail

- Table 78. Genentech, Inc. (Roche) Business Overview
- Table 79. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product
- Table 80. Genentech, Inc. (Roche) Revenue in VEGF Inhibitor Drugs Business (2018-2023) & (US\$ Million)
- Table 81. Genentech, Inc. (Roche) Recent Development
- Table 82. Merck & Co., Inc. Company Detail
- Table 83. Merck & Co., Inc. Business Overview
- Table 84. Merck & Co., Inc. VEGF Inhibitor Drugs Product
- Table 85. Merck & Co., Inc. Revenue in VEGF Inhibitor Drugs Business (2018-2023) & (US\$ Million)
- Table 86. Merck & Co., Inc. Recent Development
- Table 87. Bayer AG Company Detail
- Table 88. Bayer AG Business Overview
- Table 89. Bayer AG VEGF Inhibitor Drugs Product
- Table 90. Bayer AG Revenue in VEGF Inhibitor Drugs Business (2018-2023) & (US\$ Million)
- Table 91. Bayer AG Recent Development
- Table 92. Eli Lilly & Company Company Detail
- Table 93. Eli Lilly & Company Business Overview
- Table 94. Eli Lilly & Company VEGF Inhibitor Drugs Product
- Table 95. Eli Lilly & Company Revenue in VEGF Inhibitor Drugs Business (2018-2023) & (US\$ Million)
- Table 96. Eli Lilly & Company Recent Development
- Table 97. Research Programs/Design for This Report
- Table 98. Key Data Information from Secondary Sources
- Table 99. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global VEGF Inhibitor Drugs Market Size Comparison by Type (2023-2029) & (US\$ Million)
- Figure 2. Global VEGF Inhibitor Drugs Market Share by Type: 2022 VS 2029
- Figure 3. Tyrosine Kinase Inhibitors Features
- Figure 4. Monoclonal Antibodies Features
- Figure 5. Others Features
- Figure 6. Global VEGF Inhibitor Drugs Market Size Comparison by Application (2023-2029) & (US\$ Million)
- Figure 7. Global VEGF Inhibitor Drugs Market Share by Application: 2022 VS 2029
- Figure 8. Oncology Case Studies
- Figure 9. Ophthalmology Case Studies
- Figure 10. Others Case Studies
- Figure 11. VEGF Inhibitor Drugs Report Years Considered
- Figure 12. Global VEGF Inhibitor Drugs Market Size (US\$ Million), Year-over-Year: 2018-2029
- Figure 13. Global VEGF Inhibitor Drugs Market Size, (US\$ Million), 2018 VS 2022 VS 2029
- Figure 14. Global VEGF Inhibitor Drugs Market Share by Region: 2022 VS 2029
- Figure 15. Global VEGF Inhibitor Drugs Market Share by Players in 2022
- Figure 16. Global Top VEGF Inhibitor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Inhibitor Drugs as of 2022)
- Figure 17. The Top 10 and 5 Players Market Share by VEGF Inhibitor Drugs Revenue in 2022
- Figure 18. North America VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 19. North America VEGF Inhibitor Drugs Market Share by Country (2018-2029)
- Figure 20. United States VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 21. Canada VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 22. Europe VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 23. Europe VEGF Inhibitor Drugs Market Share by Country (2018-2029)
- Figure 24. Germany VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. France VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. U.K. VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. Italy VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Russia VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Nordic Countries VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Asia-Pacific VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Asia-Pacific VEGF Inhibitor Drugs Market Share by Region (2018-2029)

Figure 32. China VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Japan VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. South Korea VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Southeast Asia VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. India VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Australia VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Latin America VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Latin America VEGF Inhibitor Drugs Market Share by Country (2018-2029)

Figure 40. Mexico VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Brazil VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Middle East & Africa VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. Middle East & Africa VEGF Inhibitor Drugs Market Share by Country (2018-2029)

Figure 44. Turkey VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Saudi Arabia VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) &

(US\$ Million)

Figure 46. Pfizer Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2023)

Figure 47. Novartis AG Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2023)

Figure 48. GlaxoSmithKline plc Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2023)

Figure 49. Sanofi Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2023)

Figure 50. AstraZeneca plc Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2023)

Figure 51. Bristol-Myers-Squibb Company Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2023)

Figure 52. Genentech, Inc. (Roche) Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2023)

Figure 53. Merck & Co., Inc. Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2023)

Figure 54. Bayer AG Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2023)

Figure 55. Eli Lilly & Company Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2023)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

Figure 58. Key Executives Interviewed

I would like to order

Product name: Global VEGF Inhibitor Drugs Market Research Report 2023

Product link: <https://marketpublishers.com/r/G556FE525FB2EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G556FE525FB2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970